» Articles » PMID: 25924766

Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium Bovis BCG Vectors

Abstract

The well-established safety profile of the tuberculosis vaccine strain, Mycobacterium bovis bacille Calmette-Guérin (BCG), makes it an attractive vehicle for heterologous expression of antigens from clinically relevant pathogens. However, successful generation of recombinant BCG strains possessing consistent insert expression has encountered challenges in stability. Here, we describe a method for the development of large recombinant BCG accession lots which stably express the lentiviral antigens, human immunodeficiency virus (HIV) gp120 and simian immunodeficiency virus (SIV) Gag, using selectable leucine auxotrophic complementation. Successful establishment of vaccine stability stems from stringent quality control criteria which not only screen for highly stable complemented BCG ΔleuCD transformants but also thoroughly characterize postproduction quality. These parameters include consistent production of correctly sized antigen, retention of sequence-pure plasmid DNA, freeze-thaw recovery, enumeration of CFU, and assessment of cellular aggregates. Importantly, these quality assurance procedures were indicative of overall vaccine stability, were predictive for successful antigen expression in subsequent passaging both in vitro and in vivo, and correlated with induction of immune responses in murine models. This study has yielded a quality-controlled BCG ΔleuCD vaccine expressing HIV gp120 that retained stable full-length expression after 10(24)-fold amplification in vitro and following 60 days of growth in mice. A second vaccine lot expressed full-length SIV Gag for >10(68)-fold amplification in vitro and induced potent antigen-specific T cell populations in vaccinated mice. Production of large, well-defined recombinant BCG ΔleuCD lots can allow confidence that vaccine materials for immunogenicity and protection studies are not negatively affected by instability or differences between freshly grown production batches.

Citing Articles

Transcriptional Profiling of Homologous Recombination Pathway Genes in BCG Moreau.

Schwarz M, Correa P, Mendonca-Lima L Microorganisms. 2023; 11(10).

PMID: 37894192 PMC: 10609372. DOI: 10.3390/microorganisms11102534.


Auxotrophic BCG: Updates and Perspectives.

Dellagostin O, Borsuk S, Oliveira T, Seixas F Vaccines (Basel). 2022; 10(5).

PMID: 35632558 PMC: 9146772. DOI: 10.3390/vaccines10050802.


Protective efficacy of an attenuated Mtb ΔLprG vaccine in mice.

Martinot A, Blass E, Yu J, Aid M, Mahrokhian S, Cohen S PLoS Pathog. 2020; 16(12):e1009096.

PMID: 33315936 PMC: 7769599. DOI: 10.1371/journal.ppat.1009096.


Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.

Kilpelainen A, Saubi N, Guitart N, Olvera A, Hanke T, Brander C Vaccines (Basel). 2019; 7(3).

PMID: 31382453 PMC: 6789536. DOI: 10.3390/vaccines7030078.


Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.

Kilpelainen A, Saubi N, Guitart N, Moyo N, Wee E, Ravi K Front Immunol. 2019; 10:923.

PMID: 31156614 PMC: 6530512. DOI: 10.3389/fimmu.2019.00923.


References
1.
Chapman R, Shephard E, Stutz H, Douglass N, Sambandamurthy V, Garcia I . Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells. PLoS One. 2012; 7(3):e32769. PMC: 3315557. DOI: 10.1371/journal.pone.0032769. View

2.
Jain P, Hsu T, Arai M, Biermann K, Thaler D, Nguyen A . Specialized transduction designed for precise high-throughput unmarked deletions in Mycobacterium tuberculosis. mBio. 2014; 5(3):e01245-14. PMC: 4049104. DOI: 10.1128/mBio.01245-14. View

3.
Joseph J, Saubi N, Pezzat E, Gatell J . Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges. Expert Rev Vaccines. 2006; 5(6):827-38. DOI: 10.1586/14760584.5.6.827. View

4.
Saubi N, Mbewe-Mvula A, Gea-Mallorqui E, Rosario M, Gatell J, Hanke T . Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG. PLoS One. 2012; 7(8):e42559. PMC: 3424164. DOI: 10.1371/journal.pone.0042559. View

5.
Arama C, Waseem S, Fernandez C, Assefaw-Redda Y, You L, Rodriguez A . A recombinant Bacille Calmette-Guérin construct expressing the Plasmodium falciparum circumsporozoite protein enhances dendritic cell activation and primes for circumsporozoite-specific memory cells in BALB/c mice. Vaccine. 2011; 30(37):5578-84. DOI: 10.1016/j.vaccine.2011.09.054. View